Litcius/Paper detail

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

Raphael J. Morscher, Caroline Brard, Pablo Berlanga, Lynley V. Marshall, Nicolás André, Jonathan Rubino, Isabelle Aerts, Émilie De Carli, Nadège Corradini, Souad Nebchi, Xavier Paolettí, Peter G. Mortimer, Ludovic Lacroix, Gaëlle Pierron, Gudrun Schleiermacher, Gilles Vassal, Birgit Geoerger

2021European Journal of Cancer37 citationsDOIOpen Access PDF

Topics & Concepts

TopotecanMedicineTemozolomideOncologyInternal medicineTolerabilityPI3K/AKT/mTOR pathwayPopulationEverolimusPhases of clinical researchCohortChemotherapyPharmacologyAdverse effectBiologyBiochemistryEnvironmental healthApoptosisPI3K/AKT/mTOR signaling in cancerTuberous Sclerosis Complex ResearchPARP inhibition in cancer therapy
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial | Litcius